TMCnet News
bioTheranostics' New bioT3 Metastatic Cancer Solution Provides Comprehensive Genomic Testing with Integration of Next Generation SequencingSAN DIEGO --(Business Wire)-- bioTheranostics, Inc., today introduced the bioT3 Metastatic Cancer Solution, a suite of genomic-based tests that provide personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care. The commercial launch of Next Generation Sequencing (NGS), in conjunction with bioTheranostics' suite of cancer assays rebranded as bioT3 Metastatic Cancer Solution, represents a significant milestone in the company's continued efforts to deliver the right information at the right time to help patients receive the right therapy. The bioT3 product line includes:
"Patients with metastatic cancers are among the most challenging for physicians to diagnose and treat," Ding said. "Timely, accurate, and definitive diagnosis is the critical first step in personalized medicine for these patients. CancerTYPE ID continues to expand its market leadership role and has been utilized by more than 4,000 oncologists in clinical practice. At the same time, physicians also need tools to guide the selection of the most effective targeted therapies in order to improve outcomes and survival. With the addition of Next Generation Sequencing integrated with the existing biomarker panels, we now provide a comprehensive range of genomic tests for metastatic cancer. The name bioT3 creates a unified brand that more accurately represents this suite of tests and our rational approach to metastatic cancer management-offering one source for metastatic cancer solutions that provide actionable information to help address unmet medical needs." bioT3 is available now, and clinicians can order it by calling bioTheranostics' client service line at (877) 886-6739. For more information about the company's bioT3 Metastatic Cancer Solution, visit biotheranostics.com. About bioTheranostics bioTheranostics, Inc., is the leading solution provider for metastatic cancer management, leveraging its unique expertise in gene expression profiling to develop a growing array of molecular diagnostic tests for cancer patients. The company operates a CLIA-certified, CAP-accredited diagnostic laboratory to perform its proprietary tests under the bioT3 Metastatic Cancer Solution brand: CancerTYPE ID®, CancerTARGET ID, and CancerTREATMENT ID. It also offers the Breast Cancer IndexSM, which quantifies risk of recurrence of estrogen receptor-positive, lymph node-negative breast cancer. bioTheranostics, a bioMérieux company, is based in San Diego.
|